Darifenacin HBr

Catalog No.S3144 Synonyms: UK-88525

For research use only.

Darifenacin HBr (UK-88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9.

Darifenacin HBr Chemical Structure

CAS No. 133099-07-7

Selleck's Darifenacin HBr has been cited by 1 Publication

Purity & Quality Control

Choose Selective AChR Inhibitors

Other AChR Products

Biological Activity

Description Darifenacin HBr (UK-88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9.
M3 mAChR [1]
In vitro

Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat. [1] Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 µM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK cells MV7GeY5kfGmxbjDhd5NigQ>? MljORYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDi[ZRiOi2jZILlco9k\XC2b4Kg[ZhxemW|c3XkJIlvKEiHSzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDv[kBkSU2SIHzleoVtKGGodHXyJFExKG2rboOgZpkhemGmaX;pcY12dm:jc4PhfUwhTUN3ME2wMlAxODh{IN88US=> NFHGSpkzOTNzME[xNC=>
H292 cells Ml7oSpVv[3Srb36gZZN{[Xl? M3LYSGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZYRz\W6ncnfpZ{Bj\XSjMjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUDJ7MjDj[YxteyCjc4Pld5Nm\CCjczDzeIlufWyjdHnvckBw\iClQV3QJIFk[3WvdXzheIlwdiCjZoTldkA3OCCvaX7zMEBGSzVyPUCuNFE2QDVizszN NFfWPFgzOTd{M{eyOC=>
HEK293 cells NXLGe45ZTnWwY4Tpc44h[XO|YYm= NWnOXWpSSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBj\XSjMjDh[JJmdmW{Z3njJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMh[0GPUDDhZ4N2dXWuYYTpc44hfXOrbnegX|EzPUmfY1HNVEBjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBGSzVyPUCuNFAxPzl2MzFOwG0> M3r4N|I2PjJ7M{m0
CHO-K1 cells MoHHSpVv[3Srb36gZZN{[Xl? NY\ZVoZiUW6qaXLpeIlwdiCxZjDmZZN1KHOxZHn1cUBkfXK{ZX70JEhKVmFrIHnuJGNpcW6nc3WgTIFue3SncjDPeoFzgSBqQ1jPLUBMOSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJIh2dWGwIF7helEvPSCvZXHzeZJm\CC3c3nu[{BKd26Zb4Lrd{BSfWG2dILvJIF2fG:vYYTl[EBx[XSlaDDjcIFueCCybHH0[o9zdSxiSVO1NF0yNjV6NEi5JO69VQ>? MUCyOVA5Pzd3Mx?=
PC3 M{LySnBzd2yrZnXyZZRqd25iYYPzZZk> MVuxNEDPxE1iYX7kJFIxKM7:TR?= MlHPZoxw[2ujZHWgc4YhS0iUTUOgZpkh\GG{aX\lcoFkcW5iY3;1cIQh\W[oZXP0bZZmdHlicnXkeYNmKGOnbHygdJJwdGmoZYLheIlwdg>? M{TEVFI3ODdzNEi2
22Rv1 NGf5XXhRem:uaX\ldoF1cW:wIHHzd4F6 NYr1VHdUOTBizszNJIFv\CB{MDFOwG0> M4fzfIJtd2OtYXTlJI9nKEOKUl2zJIJ6KGSjcnnm[Y5i[2mwIHPveYxlKGWoZnXjeIl3\Wy7IILl[JVk\SClZXzsJJBzd2yrZnXyZZRqd25? MnzhNlYxPzF2OE[=
H1299 NH75NJJRem:uaX\ldoF1cW:wIHHzd4F6 NFvOb4cxNjQkgKOxNFAhyrWP M1SwVlczKGh? MWnzbYdvcW[rY3HueIx6KGmwaHnibZRm\CCKMUK5PUBk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NV25NYZ[OjN{OEWyOlM>
In vivo Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55%. [1] Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers. [3] Darifenacin (7.5 mg and 15 mg, daily) reduces the number of incontinence episodes per week from baseline by 67.7% and 72.8% respectively compared with 55.9% with placebo in patients with overactive bladder (OAB). Darifenacin (7.5 mg and 15 mg, daily) also shows significantly superior to placebo for improvements in micturition frequency, bladder capacity, frequency of urgency, severity of urgency and number of incontinence episodes leading to a change in clothing or pads in patients with overactive bladder (OAB). [4]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 507.46


CAS No. 133099-07-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00712322 Terminated Drug: Darifenacin Neurogenic Detrusor Overactivity Warner Chilcott October 31 2008 Phase 2
NCT00703703 Completed Drug: Darifenacin|Drug: Tolterodine|Drug: Placebo Healthy Novartis|Procter and Gamble May 2008 Phase 1
NCT00921245 Completed Drug: Darifenacin (Emselex BAY79-4998) Overactive Bladder Bayer June 2007 --
NCT00413790 Completed Drug: Darifenacin|Drug: Tolterodine|Drug: Placebo Healthy Novartis|Procter and Gamble November 2006 Phase 4
NCT00413426 Completed Drug: Darifenacin (DAR328) Healthy Novartis|Procter and Gamble June 2006 Phase 1
NCT00366002 Completed Drug: Darifenacin Overactive Bladder (OAB) Novartis|Procter and Gamble June 2006 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Darifenacin HBr | Darifenacin HBr ic50 | Darifenacin HBr price | Darifenacin HBr cost | Darifenacin HBr solubility dmso | Darifenacin HBr purchase | Darifenacin HBr manufacturer | Darifenacin HBr research buy | Darifenacin HBr order | Darifenacin HBr mouse | Darifenacin HBr chemical structure | Darifenacin HBr mw | Darifenacin HBr molecular weight | Darifenacin HBr datasheet | Darifenacin HBr supplier | Darifenacin HBr in vitro | Darifenacin HBr cell line | Darifenacin HBr concentration | Darifenacin HBr nmr